ArticleCNS drugs2022

Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) and Natalizumab Serum Concentration as Potential Biomarkers for Pharmacodynamics and Treatment Response of Patients with Multiple Sclerosis Receiving Natalizumab.

Michael Auer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.